Table 2.

Associations of patient characteristics and time to treatment.

Patient Characteristic (N = 177)	Mean Difference,a days (95% CI)
Age (> 70/≤70)	−10.2 (−25.3, 4.99)
Sex (F/M)	−3.06 (−32.5, 26.43)
Race (Nonwhite/White)	20.9 (−3.50, 45.2)
Symptomatic (N/Y)	−2.66 (−15.2, 9.83)
ECOG (≥ 2/< 2)	−5.46 (−21.2, 10.2)
Family history (N/Y)	6.06 (−12.9, 25.0)
Pack years (> 30/≤30)	−4.45 (−18.9, 10.0)
DM (N/Y)	5.01 (−10.2, 20.2)
CKD (N/Y)	2.80 (−18.0, 23.6)
COPD (N/Y)	−3.25 (−16.5, 9.98)
Any respiratory comorbidity (N/Y)	−9.24 (−23.5, 4.98)
CAD (N/Y)	6.69 (−23.7, 2.76)
Any CVD comorbidity (N/Y)	3.94 (−10.6, 18.4)
Other cancer history (N/Y)	−17.4 (−34.4, −0.47)
Alcohol dependence (N/Y)	−25.8 (−66.2, 14.6)
SCS > 9 (N/Y)	−13.6 (−26.9, −0.25)
Any psychiatric illness (N/Y)	8.43 (−1.97, 18.8)
Ventilatory defect (N/Y)
Obstructive	−4.06 (−16.8, 8.68)
Restrictive	4.29 (−23.6, 32.2)
DLCO limitation	−0.53 (−12.8, 11.7)
Tumor size < 2 cm	−3.34 (−16.0, 9.30)
SCLC (N/Y)	13.2 (6.45, 58.6)
Stage I (N/Y)	−13.7 (−26.8, −0.62)
Treatment categoryb
Surgery vs. SBRT/XRT	−17.8 (−34.7, −0.86)
Surgery vs. chemoradiation	8.95 (−1.93, 19.8)
SBRT/XRT vs. Chemoradiation	26.7 (10.4, 43.1)

CAD = coronary artery disease; CI = confidence interval; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CTB = chest tumor board; CVD = cardiovascular disease; DL_CO = diffusion capacity of the lung for carbon monoxide; DM = diabetes mellitus; ECOG PS = Eastern Cooperative Oncology Group Performance Status; FEV₁ = forced expiratory volume in 1 s; SBRT = stereotactic body radiotherapy; SCLC = small cell lung cancer; SCS = simplified comorbidity score; TLC = total lung capacity; XRT = radiotherapy.

Bolded variables: statistically significant, p < 0.05.

^aIndependent-samples tests (t-test for equality of means and Levene’s test for equality of variances).

^bIndependent-samples Kruskal-Wallis test for nonparametric distribution, p < 0.001.